| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd. Gold
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Efalizumab
CAS:214745-43-4
Purity:>95% Package:1mg/ml
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
17754423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Efalizumab
CAS:214745-43-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Efalizumab
CAS:214745-43-4
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
AntibodySystem
|
| Tel: |
18162686757 18162686757 |
| Email: |
info@biolabreagent.com |
| Products Intro: |
Product Name:Efalizumab
CAS:214745-43-4
Purity:PAGE:>95% Package:1支;1支;1支
|
|
| | EFALIZUMABUM Basic information |
| Product Name: | EFALIZUMABUM | | Synonyms: | EFALIZUMABUM;Research Grade Efalizumab(DHD41001);Efalizumab (anti-ITGAL);Hu1124|||HU 1124 | | CAS: | 214745-43-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![EFALIZUMABUM Structure]() |
| | EFALIZUMABUM Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | EFALIZUMABUM Usage And Synthesis |
| Description | Efalizumab, a humanized monoclonal antibody marketed for the treatment of
psoriasis, is a full-length IgG1 antibody developed through a murine anti-human
CD11a mAb. It is produced in a Chinese hamster ovary mammalian cell expression
system in a nutrient medium containing the antibiotic gentamicin. Psoriasis is a
disease mediated through inflammatory cells (primarily T-cells expressing CD4 or
CD8 markers) and keratinocytes. CD11a is the alpha-chain LFA-1 (leukocyte
function associate antigen; integrin family). It is expressed on the surface of Tlymphocytes
and it binds to the intercellular cell adhesion molecules (ICAM-1, -2
and -3) on endothelial cells, monocytes, keratinocytes, fibroblasts, and activated
lymphocytes. By blocking LFA-1 binding the ability of T cells to adhere, migrate
and be activated is blunted. Studies in chimpanzee and murine animal models
demonstrated that efalizumab down regulates the expression of LFA-1 on
lymphocytes, prevents contact dermatitis to 2,4-dinitrofluorobenzene, increases skin
and heart transplant survival. In the collagen-induced arthritis model it delays onset
and decreases the severity of the arthritic condition. In a study of 498 patients,
efalizumab treatment of 1 or 2 mg/kg/wk for 12 weeks provided, respectively, a 39
or 27% Psoriasis Area and Severity Score (PASI) improvement of ≥75%. By
comparison, placebo provided a 2% improvement. It was further demonstrated that a
second 12-week course could provide additional improvement. As dose increases,
clearance decreases (dose 0.1 mg/kg: 322 ml/day/kg; dose 10 mg/kg: 6.6 mL/day/kg)
with data suggesting saturation of clearance above 10 mg/mL. A pharmacokinetic
model positively correlates number of circulating cells expressing CD11a with
relative clearance. This blockade decreases the CD11a expressed on circulating
lymphocytes to about 25% of their baseline levels in patients with plaque psoriasis.
Efalizumab is formulated as a once-weekly subcutaneous injectable, dosed at 0.7 to
1 mg/kg/week. Although mild adverse events were noted such as headache, pain
chills, nausea, and fever, these events generally decreased after one or two doses.
The overall rate of infections was only 3% higher than the placebo-arm and no
depletion of T-cells was noted. | | Originator | XOMA (US) | | Uses | Treatment of transplant rejections; antipsoriatic (immunomodulator monoclonal antibody which decreases the activation, migration, and adhesion of T-cells). hu1124; anti-CD11a. | | Brand name | Raptiva |
| | EFALIZUMABUM Preparation Products And Raw materials |
|